mil60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung Cancer

Phase 3

Completed

• Conditions: Non-small Cell Lung Cancer
• Interventions: Drug: mil60; Drug: Bevacizumab

• Registration Number: NCT03196986
• Lead Sponsor: Beijing Mabworks Biotech Co., Ltd.

Brief Summary

This randomized, double-blind, multi-center phase 3 study is aimed to compare the efficacy and safety of mil60 with bevacizumab as first-line treatment when combined with standard chemotherapy (paclitaxel/carboplatin) in treatment-naive patients with advanced or recurrent non-squamous NSCLC.

Detailed Description

This is a multicenter, double-blind, randomized, parallel-group Phase 3 clinical trial evaluating the efficacy and safety of mil60 plus paclitaxel and carboplatin versus bevacizumab plus paclitaxel and carboplatin in first-line treatment for patients with advanced (unresectable, locally advanced, recurrent or metastatic) non-squamous NSCLC.The primary objective of the study was to compare the Objective Response Rate according to RECIST 1.1 of mil60 in combination with paclitaxel plus carboplatin and bevacizumab plus paclitaxel plus carboplatin in the treatment of advanced or recurrent non-squamous NSCLC subjects.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2017-06-21
• Study First Submitted QC: 2017-06-21
• Study First Posted: 2017-06-23
• Study Start: 2017-08-15
• Primary Completion: 2019-08-01
• Study Completion: 2021-07-30
• Status Verified: 2023-01
• Last Update Submitted: 2023-01-28
• Last Update Posted: 2023-01-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 517

Inclusion Criteria

• signed inform consent form(ICF)
• Aged 18-75 years, male or female
• Histologically or cytologically documented inoperable, local advanced (stage IIIB), metastatic (stage IV), or recurrent non-squamous NSCLC
• At least one measurable lesion according to Response Evaluation Criteria In Solid Tumors（RECISIT） v 1.1
• Eastern Cooperative Oncology Group(ECOG) performance status of 0 or 1
• Life expectancy ≥ 12 weeks
• Patients of childbearing potential must agree to use effective contraceptive measures during study treatment and for 6 months after receiving last study treatment

Read More

Exclusion Criteria

• Mixed non-small cell lung cancer with squamous cell carcinoma component, or small cell carcinoma
• Patients with known Anaplastic Lymphoma Kinase（ALK） or C-Ros Oncogene 1 Receptor Tyrosine Kinase （ROS1）rearrangement
• History of hemoptysis within 3 months prior to screening with blood volume more than 2.5 mL
• Evidence of tumor invading major blood vessels on imaging
• Patients with brain metastasis, spinal cord compression or carcinomatous meningitis history
• Uncontrolled hypertension, prior history of hypertensive crisis and hypertensive encephalopathy
• Clinically significant cardiovascular disease but not limited to active infections; unstable angina; stroke or transient cerebral ischemia; myocardial infarction; congestive heart-failure; serious cardiac arrhythmia, hepatic, renal or metabolic disease requiring medication during the study
• History of radical radiotherapy to the thorax within 6 months
• Serious, non-healing wound, active ulcer, or untreated bone fracture, or major surgical procedure within 28 days prior to randomization or anticipation of need for major surgery during the course of the study
• Recent or current treatment with aspirin or other non-steroidal anti-inflammatory drugs (NSAID) known to inhibit platelet function within 10 days prior to first dose of study treatment
• Recent or current treatment with anticoagulants or thrombolytic agent within 10 days prior to first dose of study treatment

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
mil60	mil60	mil60 (15mg/kg) was co-administered intravenously with 4 to 6-cycle paclitaxel/carboplatin, non-progressive patients are then given with maintenance single-agent mil60 (7.5mg/kg) until disease progression, intolerable toxicity, or withdrawal.
Bevacizumab	Bevacizumab	Bevacizumab (15mg/kg) was co-administered intravenously with 4 to 6-cycle paclitaxel/carboplatin, non-progressive patients are then given with maintenance single-agent mil60 (7.5mg/kg) until disease progression, intolerable toxicity, or withdrawal.

Primary Outcome Measures

Name	Time	Method
Objective response rate	24 months	Percentage of patients with complete remission or partial response

Secondary Outcome Measures

Name	Time	Method
Overall survival	30 months	the time from randomisation to death from any cause
Progression-free survival	24 months	Interval between randomization and disease progression or death
Objective response rate	26 months	Percentage of patients with complete remission or partial response
Duration of response	24 months	Interval from the onset of a complete remission or partial response until evidence of disease progression or death
Disease control rate	24 months	Percentage of patients with complete remission, partial response and stable disease

Trial Locations

Locations (2)

Cancer Institute/Hospital, Chinese Academy of Medical Sciences; 🇨🇳 Beijing, China

Peking University Shenzhen Hospital; 🇨🇳 Shenzhen, China